| __timestamp | Bausch Health Companies Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 1860000 |
| Thursday, January 1, 2015 | 2682700000 | 2963000 |
| Friday, January 1, 2016 | 2810000000 | 6961000 |
| Sunday, January 1, 2017 | 2582000000 | 11779000 |
| Monday, January 1, 2018 | 2473000000 | 13697000 |
| Tuesday, January 1, 2019 | 2554000000 | 15749000 |
| Wednesday, January 1, 2020 | 2367000000 | 18638000 |
| Friday, January 1, 2021 | 2624000000 | 27196000 |
| Saturday, January 1, 2022 | 2625000000 | 31739000 |
| Sunday, January 1, 2023 | 2917000000 | 33491000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Bausch Health Companies Inc. and Protagonist Therapeutics, Inc. from 2014 to 2023.
Bausch Health, a major player, consistently reported high SG&A expenses, peaking at approximately $2.9 billion in 2023. This represents a 44% increase from 2014, reflecting strategic investments in marketing and administration.
In contrast, Protagonist Therapeutics, a smaller biotech firm, saw its SG&A expenses grow from $1.9 million in 2014 to $33.5 million in 2023, a staggering 1,700% increase. This growth underscores its aggressive expansion and development strategies.
This comparison highlights the diverse financial strategies within the pharmaceutical sector, offering insights into how companies allocate resources to drive growth.
Sanofi and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Bausch Health Companies Inc.
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Bausch Health Companies Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.